STOCK TITAN

Nasdaq panel restores Vivakor (NASDAQ: VIVKD) listing with 1-year monitor

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Vivakor, Inc. reports that a Nasdaq Hearing Panel has determined the company is back in compliance with Nasdaq’s Minimum Bid Price Requirement. The decision follows a 1-for-200 reverse stock split of its common stock completed on March 24, 2026.

Nasdaq has notified Vivakor that trading in its securities will resume on the exchange effective April 27, 2026. The company will be under a Mandatory Panel Monitor for one year, during which any new bid-price deficiency could lead quickly to a delisting determination.

Positive

  • Nasdaq trading to resume: A Nasdaq Hearing Panel determined Vivakor now complies with the Minimum Bid Price Requirement, and Nasdaq informed the company that trading in its securities will resume on the exchange effective April 27, 2026.

Negative

  • One-year heightened monitoring: Vivakor will be subject to a one-year Mandatory Panel Monitor. If it again falls below the Minimum Bid Price Requirement, staff will issue a Delisting Determination Letter without first considering a new compliance plan at the staff level.

Insights

Vivakor regains Nasdaq compliance, but faces a one‑year probation period.

Vivakor had fallen below Nasdaq’s $1.00 minimum bid price and then under the Low Priced Stocks Rule after its stock traded at $0.10 or less for ten consecutive days, resulting in a trading suspension.

To restore compliance, the company executed a 1-for-200 reverse stock split, which increased the per-share price enough for a Nasdaq Hearing Panel to find it meets the Minimum Bid Price Requirement. Trading on Nasdaq is set to resume on April 27, 2026.

Under a one-year Mandatory Panel Monitor, any new shortfall on the bid-price rule will prompt a Delisting Determination Letter without a staff-level remediation phase. The company could still present a compliance plan directly to the Panel if that occurs.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice or transferred its listing to a different exchange.
Reverse stock split ratio 1-for-200 Reverse stock split of common stock effected March 24, 2026
Minimum bid price threshold $1.00 per share Nasdaq Listing Rule 5550(a)(2) Minimum Bid Price Requirement
Low Priced Stocks Rule trigger $0.10 or less for 10 days Closing bid price condition under Listing Rule 5810(c)(3)(A)(iii)
Mandatory monitoring period 1 year Mandatory Panel Monitor from April 23, 2026 letter
Trading resumption date April 27, 2026 Date Nasdaq will resume trading in Vivakor securities
Minimum Bid Price Requirement regulatory
"requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”)"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Low Priced Stocks Rule regulatory
"subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”)"
reverse stock split financial
"the Company effected a 1-for-200 reverse stock split of the Common Stock"
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
Mandatory Panel Monitor regulatory
"the Company will be subject to a Mandatory Panel Monitor for a period of one year"
A mandatory panel monitor is an independent group tasked with regularly reviewing safety and key results during a clinical trial or regulated program to protect participants and ensure the study is conducted properly. For investors, this matters because the panel can recommend changes, pauses, or early stopping of a trial — actions that can speed up, delay, or quietly derail a program and therefore materially affect a company’s timeline and value, much like a referee whose calls change the outcome of a game.
false 0001450704 0001450704 2026-04-23 2026-04-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 23, 2026

 

VIVAKOR, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-41286   26-2178141
(State or other jurisdiction of   (Commission   (IRS Employer
incorporation or organization)   File Number)   Identification No.)

 

5220 Spring Valley Rd. Suite 500

Dallas, TX 75254

(Address of principal executive offices)

 

(469) 480-7175

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   VIVK   The Nasdaq Stock Market LLC
(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 

 

 

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

As previously disclosed, on March 18, 2025, Vivakor, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”) listed on Nasdaq was below $1.00 per share for 30 consecutive business days, the Company did not comply with Listing Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”).

 

As previously disclosed, on December 19, 2025, the Company received a notification letter (the “Letter”) from the Staff that as of December 19, 2025, the Common Stock had a closing bid price of $0.10 or less for ten consecutive trading days and accordingly, the Company was subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”).

 

The trading of the Common Stock was suspended at the opening of business on December 26, 2025.

 

As previously disclosed, on December 24, 2025, the Company submitted an appeal to the Staff’s determination described in the Letter, and a hearing was held on January 29, 2026. On March 24, 2026, the Company effected a 1-for-200 reverse stock split of the Common Stock in order to satisfy the Minimum Bid Price Requirement.

 

On April 23, 2026, the Company received a notification letter (the “April Letter”) from the Staff that the Nasdaq Hearing Panel (the “Panel”) has determined that the Company is in compliance with the Minimum Bid Price Requirement and that trading in the Company’s securities will resume trading on the Exchange effective April 27, 2026. Pursuant to Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor for a period of one year from the date of the April Letter. In the event that the Company becomes deficient with the Minimum Bid Price Requirement, the Company will not be afforded the opportunity to submit a compliance plan for the Staff’s consideration and the Staff will issue a Delisting Determination Letter, following which the Company may request review by the Panel, at which the Company may present a compliance plan for the Panel’s consideration.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VIVAKOR, INC.
     
Dated: April 28, 2026 By: /s/ James Ballengee
    Name:  James Ballengee
    Title: Chief Executive Officer

 

2

FAQ

What did Vivakor (VIVKD) announce about its Nasdaq listing status?

Vivakor announced that a Nasdaq Hearing Panel determined the company is back in compliance with the Minimum Bid Price Requirement. As a result, Nasdaq informed Vivakor that trading in its securities will resume on the exchange effective April 27, 2026, ending the prior suspension.

Why was Vivakor previously at risk of Nasdaq delisting?

Vivakor previously received notices because its common stock’s closing bid price stayed below $1.00 for 30 consecutive business days. It later triggered Nasdaq’s Low Priced Stocks Rule when the closing bid was $0.10 or less for ten consecutive trading days, leading to suspension and an appeal hearing.

How did Vivakor regain compliance with Nasdaq’s bid-price rule?

Vivakor effected a 1-for-200 reverse stock split of its common stock on March 24, 2026. This corporate action increased the per-share trading price, allowing the Nasdaq Hearing Panel to conclude the company now meets the Minimum Bid Price Requirement for continued listing on the exchange.

When will Vivakor’s shares start trading again on Nasdaq?

Nasdaq notified Vivakor that trading in its securities will resume on the exchange effective April 27, 2026. This follows the Panel’s determination that the company is back in compliance with the Minimum Bid Price Requirement after implementing a 1-for-200 reverse stock split in March 2026.

What is the Mandatory Panel Monitor period for Vivakor?

Under Listing Rule 5815(d)(4)(B), Vivakor will be subject to a Mandatory Panel Monitor for one year from the April 23, 2026 letter. During this time, any new failure to meet the Minimum Bid Price Requirement will trigger a Delisting Determination Letter without a prior staff-level remediation phase.

What happens if Vivakor again fails the Minimum Bid Price Requirement?

If Vivakor again becomes deficient with the Minimum Bid Price Requirement during the monitoring period, Nasdaq staff will issue a Delisting Determination Letter. The company could then request review by the Panel and present a compliance plan directly to the Panel for consideration at a subsequent hearing.

Filing Exhibits & Attachments

3 documents